Health Department officials told a Senate Estimates hearing yesterday that they are monitoring the US 'Most Favored Nation' pharmaceutical pricing policy closely, developing responses as necessary, and continue to see a steady stream of submissions and reimbursement outcomes.
Latest Video
New Stories
-
UQ drug QED-203 moves toward first in human trials with Ellison Medical Institute backing
June 24, 2026 - - Australian Biotech -
Watching this system has become like cheering for an elephant on a unicycle
June 24, 2026 - - Latest News -
Tax deal delays NDIS overhaul and reopens scrutiny with inquiry extension
June 24, 2026 - - Latest News -
Access delays in cancer medicines are costing Australia productivity, livelihoods, and lives
June 23, 2026 - - Latest News -
US launches investigation into pharmaceutical pricing with potential broad implications
June 23, 2026 - - Latest News -
If we're incapable of delivering meaningful change, we should hope the US intervenes
June 23, 2026 - - Latest News -
'AUScelerate' emerges as new name for MTPConnect ahead of BIO 2026
June 22, 2026 - - Australian Biotech


